New Investor as of July 2013, but small biotech Investor.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For sure. Especially given all they know about Leronlimab’s safety and efficacy. But it is what it is. It is a shame though.
That wasn’t my question. But thanks for answering mine.
So the answer is no. The “we” does not mean shareholders per se.... Regardless of the reason suggested or actual. So rather than assume why, why not just wait until that information is clear and evident. Seems the intelligent thing to do.
So humorous to see Leronlimab not even mentioned. Not Cytodyn.
Big pharma doesn’t want any extra spot light on a drug that potentially disrupt a whole pipeline, or a whole company for that matter.
Data is king. Bring on the data! Leronlimab for the win!
It’s use in Covid was understandable given the more anecdotal time to discharge improvement. To use the term “standard of care” for its use was a step too far, imo.
Question is: If Leronlimab (or any other drug for that matter) significantly beats remdesivir in terms of efficacy, will there be a new standard of care?
Was Michael Mulholland saying that shareholders would get that letter, or Cytodyn? Because I kind of understand the “we” to be management. No guarantee at all made about shareholders seeing or even hearing about that letter, per se.
Rockleo, I would wonder about that...
If a patient is experiencing elevated liver function as a result of receiving remdesivir, one would think that they would no longer qualify for the drug since that is an exclusionary criteria for use of remdesivir. If that is a possible scenario, it could also be that Leronlimab could show added benefit as liver function improves once remdesivir is discontinued.
I guess this is another reason why the data needs a good amount of time to work on.
It’s stat news. What else is there to say. Mis-reading is what they do. It’s called un-professionalism. They excel at it. That’s why he can read a 63% decrease in SAEs in the Leronlimab Covid trials as something negative. Either it’s pure ignorance, or purposeful disingenuousness.
Either way, that style of ‘journalism’ is a joke. And now we see with Novavax that the apple doesn’t fall far from the tree. No ethics. How can someone live with themselves like that. Thank God AF’s wife took care of her own mother during her last days.
Pretty much a reiteration of what I believe. Especially with Covid. That’s because the inflammatory cascade is what’s being tackled with the Covid trial. Excellent data there means likely a high statistical significance of any inflammatory condition Leronlimab tackles.
Long CYDY! See you in December!
Always appreciate your insights, Black Ops. Hoping this will get moving with Covid data. Hoping for this week, but I’m shooting for the following week. Every nugget of statistical data counts.
Yep. It’s results. The call will likely be taken advantage of by shorts. Possibly another great time to top off.
Not that I’m bashing, but this is from December 2016. I would love to hear an update from him now.
Ha ha. Right?
That’s kind of what I thought. Just wanted to confirm I was reading it right.
Can someone explain this to us that don’t quite have the finer details of the corporate Investing scene?
Roche’s IL-6 repurposing theory goes bust.
https://endpts.com/roche-declares-a-phiii-failure-for-covid-19-as-the-il-6-repurposing-theory-bites-the-dust/
I guess you can’t teach an old dog new tricks. This continues to narrow the playing field of Covid therapies. #Leronlimab for the win!
If that’s all they got, then Cytodyn has it in the bag.
That is awesome. It’s like everything about this company and the drug gets better and better.
Exactly.
Anyone who calls the buyers strike piece an interesting read hasn’t read much in their lifetime. Lol.
So a poster follows up a post with another statement. Wow. Big news there. Conspiracy. Close up shop. It’s all done.
#LERONLIMAB doesn’t work now! The fda should have stopped the trials due to no Statistical significance!
Oh... wait....
For which vaccine?
Is there any vaccine tested in a placebo controlled study?
https://www.nbcnews.com/news/amp/ncna1234883
Joseph Petrosino, the chair of virology and microbiology at the Baylor College of Medicine, said: “ I think one of the nice things about the CDC recommendation was that they pulled together a lot of data from a lot of different places from around the world that show that a lot of these long-term shedders are not associated with new infections or virus transmission.”
So what’s the difference between an asymptomatic carrier and a long term shedder? Nothing. So what makes a shedder able to transmit? Symptoms.
In other words, non-symptomatic carriers are not infectious.
We actually had a patient at the hospital I work at test negative twice, but had symptoms, then tested positive the third time. What changed? Nothing except a positive test. The symptoms had always been there. It’s the symptoms that contribute to infectious-ness, not just a positive test alone.
Exactly.
We soon will be! Lol!
And you must not have realized that they could potentially still get approved. Your bad! ;-P
Of course NIH selects it! Leronlimab is already done with its trial and about to crush it with data.
See you in December!
Exactly. Anyone who knows how this drug works can understand the reason to buy massively. They used it in HIV and it worked phenomenally. The used in cancer, and it worked phenomenally. Now they are using it for Covid. And if the results are phenomenal, it will speak volumes to its use in every other inflammatory condition they aim for.
Leronlimab is setting up to be the drug of the century.
Who cares. For Longs, it’s about the price AFTER approval, not before.
The Gov clinical trial Site is notorious for not being updated regularly.
Exactly.
Thanks Leron. Weeks, yes, but years?.... nah.
I wasn’t referring to the analysis portion per se, but some medications need long periods of follow up to determine a long term efficacy. Like I said, rare. But I wasn’t referring to the compilation of data, but rather the long term following of patients to determine that a therapy is working.
No. Not years. Never does it take that long expect for very small and unique situations. This is a drug whose MOA and laboratory effects can be analyzed relatively quickly. It’s the statistical portion that takes time, usually a week to three weeks.
In regards to years, I’d have to listen again to his words to specifically know what you’re referring to.
I was merely pointing out that NvAX is on the Nasdaq. The ability to manipulate the price and cause it to drop so volatile is not nearly the same potential as Cytodyn on the otc. So to claim the price truly reflects what he says is comparing apples to oranges.
Is novavax on the Nasdaq? Why, yes it is.
Awesome response. It’s AF’s pick and choose, a la Carte response that demonstrates an overt and shameful bias in reporting ALL information. It’s a confirmation that he doesn’t care, which tells me more about his character.
Yeah, if anything, Longs will be rewarded even greater when they read between the lines and take advantage of the short attacks and continue to load up. It’s a matter of time, specifically uplifting, when a lot of these short attacks will become more difficult.
The science is still solid. The trial was never stopped due to efficacy not being there, which would have been a statistically significant reason to stop the trial... another point that AF doesn’t mention!
Yeah. In case it wasn’t clear, my post was actually rhetorical! Lol. And me either. I have more ethics than live like that.
Exactly. The issue will be best settled when people have to decide whether he purposefully deceived people, or was woefully ignorant and uninformed when he stated that Cytodyn wouldn’t be able to help Covid patients when Statistical and clinical news comes out.